COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in research, innovative therapies, and patient care.
COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma (MM), the congress brought together leading experts from around the world to discuss the latest advances in research, novel therapies, and patient care.
COMy 2026 | Professor Shaji Kumar: An Early Look at the Landmark Changes in the New Multiple Myeloma Response Criteria

COMy 2026 | Professor Shaji Kumar: An Early Look at the Landmark Changes in the New Multiple Myeloma Response Criteria

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in translational research, novel therapeutics, and patient care.
COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma and related plasma cell disorders, the congress brought together leading experts worldwide to discuss the latest advances in translational research, novel therapeutics, and patient care.
COMy 2026 | Honoring the Architects of Progress: Major Awards Spotlight the Past, Present, and Future of Multiple Myeloma Research

COMy 2026 | Honoring the Architects of Progress: Major Awards Spotlight the Past, Present, and Future of Multiple Myeloma Research

From May 14–17, 2026, the 12th International Congress on Controversies in Multiple Myeloma (COMy 2026) was successfully held in Paris, France. Recognized as one of the most influential academic meetings in the field of multiple myeloma (MM), COMy has long been distinguished by its focused format, in-depth scientific discussions, and emphasis on unresolved clinical questions.
Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Dr. Ludovico Docimo, Professore Ordinario e Primario of the UOC of General, Minimally Invasive and Obesity Surgery at the University of Campania "Luigi Vanvitelli" (Italy), shared his view that robotic surgery will transform colorectal operating rooms, much like laparoscopy did.
From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was convened in Hangzhou, Zhejiang Province. Prof. Zhang Suzhan from the Second Affiliated Hospital, Zhejiang University School of Medicine attended the meeting and shared his insights on colorectal cancer screening, precision MDT management, and localized Chinese clinical solutions.
ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line treatment for HR-positive/HER2-negative advanced breast cancer and have significantly improved patient outcomes. However, in real-world clinical practice, a subset of patients still experiences rapid disease progression early during treatment, suggesting the presence of more aggressive tumor biology and potential intrinsic endocrine resistance mechanisms.
Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Against the backdrop of Chongqing’s mountainous skyline and flowing rivers, the 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference were successfully held in Chongqing from April 15–19, 2026.